



ASX ANNOUNCEMENT

Mike Ryan Appointed to the Board as Chairman

1 December 2025 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to advise that Mr Mike Ryan has been appointed to the board of Cann Group Limited effective today to fill a casual vacancy and will also be appointed Chairman.

Mr Ryan replaces Mr Doug Rathbone as Chairman. Mr Rathbone will remain a valued member of the Board of Directors.

Mike has over 40 years of experience in the financial services sector. He has an extensive track record in strategic planning, organisational growth and stakeholder engagement and experience in leading financial services businesses in Australia and globally. He previously held senior roles including Head of Equities at Shaw and Partners, Managing Director and Head of Equities & Operations at CIMB, Executive Director at Goldman Sachs, and Head of Australian Equities Distribution at Morgan Stanley. He currently Chairs Sequoia Financial Group (ASX: SEQ) and serves as a director of Energy One (ASX: EOL) and PM Capital Global Opportunities Fund (ASX: PGF).

Mr Ryan said, "I'd like to thank Doug for his stewardship of the Company in his role as Chairman and the Board more generally for their trust and confidence in me. I look forward to working closely with the Board and management team to continue driving Cann's strategic objectives and delivering value for shareholders."

Mr Rathbone said, "I have great confidence in Mike's leadership and experience. His appointment as Chairman marks an exciting new chapter for Cann, and I look forward to supporting him and the Board as we continue to build on the Company's strong foundations."

Authorised for release by the Board of Directors, Cann Group Limited.

For all other information please contact:

Jenni Pilcher
CEO & Managing Director
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Steven Notaro
Company Secretary
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouponlimited.com | www.satipharm.com